The Biopharmaceutical Excipient Manufacturing Market Size is valued at 1259.8 Million in 2022 and is predicted to reach 2624.3 Million by the year 2030 at a 9.7 % CAGR during the forecast period for 2023-2031.
Excipients are carrier agents beneficial for biopharmaceutical formulations. They offer efficient binding of ingredients, increase drug stability in the dosage form and modify the solubility of API. Excipients are inert, reproducible substances created from minerals, sugar, wheat, corn, and other such ingredients. They can reduce operating costs, enhance productivity, and improve product quality.
Major driving factors of the biopharmaceutical excipient manufacturing market are the surging applications of excipients, increasing initiatives by market players to develop excipients for innovating high-quality drugs, growing focus on the development of novel drugs, rising cases of chronic diseases, increasing use of lipid and sucrose-based excipients, advances in the field of pharmaceutical manufacturing, and the increasing R&D activities in the pharmaceutical industries. The increasing COVID cases have increased the drug manufacturing burden of biopharmaceutical companies to treat the affected patients. Hence, companies are rising their focus on fast drug development. Excipients are effective and efficient in enhancing the manufacturing process for biopharmaceuticals.
Therefore, the demand for biopharmaceutical excipients is surging to develop innovative and stabilized drugs, thereby creating significant growth opportunities during the forecast period. However, complexities associated with drug manufacturing along with the requirement of high capital investments may hinder the market growth during the forecast period.
Market Segmentation
The biopharmaceutical excipient manufacturing market is segmented based on the type of biologics, Product Type, scale of operation, and region. The type of biologics segment comprises antibodies, vaccines, cell therapies, and other biologics. The product type market is categorized into carbohydrates, solubilizers/surfactants, polyols, and specility excipients. The carbohydrates segment is expected to dominate this market in the forthcoming years due to the rising use of carbohydrate-based excipient products such as sucrose and starch in drug formulations. By scale of operation, the market is classified into preclinical, clinical, and commercial. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Asia-Pacific is estimated to be the rapidly growing regional market in the next few years due to the increasing incidences of chronic diseases, rising government funding for healthcare, and the growing demand for drugs. India and China are the emerging countries of this market
Competitive Landscape
Some Of The Key Players In The Biopharmaceutical Excipient Manufacturing Market:
- ABITEC Corporation
- Aceto
- Angus Chemical
- Apothecon
- Ashland Global
- Associated British Foods plc
- Avantor
- BASF SE
- BioSpectra
- BOC Sciences
- G. Group
- Clariant
- Colorcon
- Croda International Plc
- DFE Pharma
- DOW
- Eastman Chemical
- Evonik Industries AG
- IMCD N.V.
- Innophos
- Invitria
- RETTENMAIER & SÖHNE GmbH + Co KG
- Kirsch Pharma
- Meggle Pharma
- Merck KGaA
- Novo Nordisk
- Pfanstiehl, Inc.
- Pharmonix
- Roquette Freres
- Shin-Etsu Chemical
- Sigachi Industries Limited
- Signet Excipients Pvt. Ltd (IMCD)
- Spectrum Chemical Manufacturing Corp.
- SPI Pharma
- Stepan Company
- Tereos
- The Lubrizol
- Wacker Chemie
The Biopharmaceutical Excipient Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1259.8 Billion |
|
Revenue Forecast In 2030 |
USD 2624.3 Million |
|
Growth Rate CAGR |
CAGR of 9.7 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2030 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, By Type of Biologics, By Scale Of Operation |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
ABITEC Corporation, Aceto, Angus Chemical, Apothecon, Ashland Global, Associated British Foods plc, Avantor, BASF SE, BioSpectra, BOC Sciences, C.G. Group, Clariant, Colorcon, Croda International Plc, DFE Pharma, DOW, Eastman Chemical, Evonik Industries AG, IMCD N.V., Innophos, Invitria, J. RETTENMAIER & SÖHNE GmbH + Co KG, Kirsch Pharma, Meggle Pharma, Merck KGaA, Novo Nordisk, Pfanstiehl, Inc., Pharmonix, Roquette Freres, Shin-Etsu Chemical, Sigachi Industries Limited, Signet Excipients Pvt. Ltd (IMCD), Spectrum Chemical Manufacturing Corp., SPI Pharma, Stepan Company, Tereos, The Lubrizol, Wacker Chemie, |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
